200 related articles for article (PubMed ID: 29297493)
1. The Genomics of Prostate Cancer: emerging understanding with technologic advances.
Rubin MA; Demichelis F
Mod Pathol; 2018 Jan; 31(S1):S1-11. PubMed ID: 29297493
[TBL] [Abstract][Full Text] [Related]
2. SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer.
Hernández-Llodrà S; Segalés L; Safont A; Juanpere N; Lorenzo M; Fumadó L; Rodríguez-Vida A; Cecchini L; Bellmunt J; Lloreta-Trull J
Prostate; 2019 Jul; 79(10):1156-1165. PubMed ID: 31090082
[TBL] [Abstract][Full Text] [Related]
3. ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis.
Bose R; Karthaus WR; Armenia J; Abida W; Iaquinta PJ; Zhang Z; Wongvipat J; Wasmuth EV; Shah N; Sullivan PS; Doran MG; Wang P; Patruno A; Zhao Y; ; Zheng D; Schultz N; Sawyers CL
Nature; 2017 Jun; 546(7660):671-675. PubMed ID: 28614298
[TBL] [Abstract][Full Text] [Related]
4. Clinical and genomic features of SPOP-mutant prostate cancer.
Nakazawa M; Fang M; H Marshall C; Lotan TL; Isaacsson Velho P; Antonarakis ES
Prostate; 2022 Feb; 82(2):260-268. PubMed ID: 34783071
[TBL] [Abstract][Full Text] [Related]
5. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.
Barbieri CE; Baca SC; Lawrence MS; Demichelis F; Blattner M; Theurillat JP; White TA; Stojanov P; Van Allen E; Stransky N; Nickerson E; Chae SS; Boysen G; Auclair D; Onofrio RC; Park K; Kitabayashi N; MacDonald TY; Sheikh K; Vuong T; Guiducci C; Cibulskis K; Sivachenko A; Carter SL; Saksena G; Voet D; Hussain WM; Ramos AH; Winckler W; Redman MC; Ardlie K; Tewari AK; Mosquera JM; Rupp N; Wild PJ; Moch H; Morrissey C; Nelson PS; Kantoff PW; Gabriel SB; Golub TR; Meyerson M; Lander ES; Getz G; Rubin MA; Garraway LA
Nat Genet; 2012 May; 44(6):685-9. PubMed ID: 22610119
[TBL] [Abstract][Full Text] [Related]
6. Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis.
Sandoval GJ; Pulice JL; Pakula H; Schenone M; Takeda DY; Pop M; Boulay G; Williamson KE; McBride MJ; Pan J; St Pierre R; Hartman E; Garraway LA; Carr SA; Rivera MN; Li Z; Ronco L; Hahn WC; Kadoch C
Mol Cell; 2018 Aug; 71(4):554-566.e7. PubMed ID: 30078722
[TBL] [Abstract][Full Text] [Related]
7. SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG.
Shoag J; Liu D; Blattner M; Sboner A; Park K; Deonarine L; Robinson BD; Mosquera JM; Chen Y; Rubin MA; Barbieri CE
J Clin Invest; 2018 Jan; 128(1):381-386. PubMed ID: 29202479
[TBL] [Abstract][Full Text] [Related]
8. Genetic Progression of High Grade Prostatic Intraepithelial Neoplasia to Prostate Cancer.
Jung SH; Shin S; Kim MS; Baek IP; Lee JY; Lee SH; Kim TM; Lee SH; Chung YJ
Eur Urol; 2016 May; 69(5):823-30. PubMed ID: 26542946
[TBL] [Abstract][Full Text] [Related]
9. SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling.
Blattner M; Liu D; Robinson BD; Huang D; Poliakov A; Gao D; Nataraj S; Deonarine LD; Augello MA; Sailer V; Ponnala L; Ittmann M; Chinnaiyan AM; Sboner A; Chen Y; Rubin MA; Barbieri CE
Cancer Cell; 2017 Mar; 31(3):436-451. PubMed ID: 28292441
[TBL] [Abstract][Full Text] [Related]
10. Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer.
Bernasocchi T; El Tekle G; Bolis M; Mutti A; Vallerga A; Brandt LP; Spriano F; Svinkina T; Zoma M; Ceserani V; Rinaldi A; Janouskova H; Bossi D; Cavalli M; Mosole S; Geiger R; Dong Z; Yang CG; Albino D; Rinaldi A; Schraml P; Linder S; Carbone GM; Alimonti A; Bertoni F; Moch H; Carr SA; Zwart W; Kruithof-de Julio M; Rubin MA; Udeshi ND; Theurillat JP
Nat Commun; 2021 Feb; 12(1):734. PubMed ID: 33531470
[TBL] [Abstract][Full Text] [Related]
11. Genomic alterations related to HPV infection status in a cohort of Chinese prostate cancer patients.
Lang B; Cao C; Zhao X; Wang Y; Cao Y; Zhou X; Zhao T; Wang Y; Liu T; Liang W; Hu Z; Tian X; Zhang J; Yan Y
Eur J Med Res; 2023 Jul; 28(1):239. PubMed ID: 37461056
[TBL] [Abstract][Full Text] [Related]
12. SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence.
Hernández-Llodrà S; Segalés L; Juanpere N; Marta Lorenzo T; Salido M; Nonell L; David López T; Rodríguez-Vida A; Bellmunt J; Fumadó L; Cecchini L; Lloreta-Trull J
Prostate; 2021 Dec; 81(16):1267-1277. PubMed ID: 34533858
[TBL] [Abstract][Full Text] [Related]
13. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells.
Zong Y; Xin L; Goldstein AS; Lawson DA; Teitell MA; Witte ON
Proc Natl Acad Sci U S A; 2009 Jul; 106(30):12465-70. PubMed ID: 19592505
[TBL] [Abstract][Full Text] [Related]
14. Co-occurrent Alterations of Alzheimer's Genes and Prostate Cancer Genes in Prostate Cancer.
Lehrer S; Rheinstein PH
Cancer Genomics Proteomics; 2020; 17(3):271-275. PubMed ID: 32345668
[TBL] [Abstract][Full Text] [Related]
15. Distinct genomic aberrations associated with ERG rearranged prostate cancer.
Demichelis F; Setlur SR; Beroukhim R; Perner S; Korbel JO; Lafargue CJ; Pflueger D; Pina C; Hofer MD; Sboner A; Svensson MA; Rickman DS; Urban A; Snyder M; Meyerson M; Lee C; Gerstein MB; Kuefer R; Rubin MA
Genes Chromosomes Cancer; 2009 Apr; 48(4):366-80. PubMed ID: 19156837
[TBL] [Abstract][Full Text] [Related]
16. Genetic, Environmental, and Nuclear Factors Governing Genomic Rearrangements.
Ramanand SG; Mani RS
Adv Exp Med Biol; 2019; 1210():57-66. PubMed ID: 31900904
[TBL] [Abstract][Full Text] [Related]
17. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects.
Frank S; Nelson P; Vasioukhin V
F1000Res; 2018; 7():. PubMed ID: 30135717
[TBL] [Abstract][Full Text] [Related]
19. SPOP mutations in prostate cancer across demographically diverse patient cohorts.
Blattner M; Lee DJ; O'Reilly C; Park K; MacDonald TY; Khani F; Turner KR; Chiu YL; Wild PJ; Dolgalev I; Heguy A; Sboner A; Ramazangolu S; Hieronymus H; Sawyers C; Tewari AK; Moch H; Yoon GS; Known YC; Andrén O; Fall K; Demichelis F; Mosquera JM; Robinson BD; Barbieri CE; Rubin MA
Neoplasia; 2014 Jan; 16(1):14-20. PubMed ID: 24563616
[TBL] [Abstract][Full Text] [Related]
20. CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage.
Zhu Y; Wen J; Huang G; Mittlesteadt J; Wen X; Lu X
Prostate; 2021 Jan; 81(1):81-88. PubMed ID: 33022763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
